NeuroBo Pharmaceuticals Inc NRBO claims its DA-1726, an unique oxyntomodulin analog working as a glucagon-like peptide-1 receptor as well as glucagon receptor twin agonist, had actually been revealed to evoke remarkable weight-loss efficiency contrasted to Semaglutide as well as Tirzepatide in preclinical screening.
Novo Nordisk A/S’s NVO Semaglutide is marketed under Ozempic, Wegovy as well as Rybelsus. Tirzepatide is marketed under Mounjaro by Eli Lilly And Also Carbon Monoxide LLY
DA-1726 showed weight-loss efficiency in diet-induced overweight (DIO) rats (32.6% for DA-1726 at a high dosage vs. 24.0% for semaglutide, p<< 0.05).
The low-dose DA-1726 team revealed a comparable result contrasted to semaglutide in spite of eating extra food. The high-dose DA-1726 team revealed comparable food consumption as SEMA, nonetheless, it brought about a greater weight-loss result.
DA-1726 (250 as well as 500 nmol/kg) caused tiny however considerable weight-loss 3 days after a solitary shot (-7.6% as well as -9.5% vs. control).
The medicinal result of DA-1726 was examined contrasted to various other rival peptides. DA-1726 revealed remarkable efficiency contrasted to cotadutide (COTA) in lowering body weight (14.4% for DA-1726 as well as 6.4% for COTA vs. diet-induced overweight (DIO) computer mice manage at 30 nmol/kg, p<< 0.05) as well as boosting plasma sugar, insulin, as well as Homeostatic Version Analysis for Insulin Resistance (HOMA-IR) (-91% for DA-1726 vs. -52% for COTA) in DIO computer mice.
DA-1726 revealed remarkable plasma triglyceride (TG) decrease as well as a comparable decrease of complete cholesterol (T-CHO) contrasted to cotadutide.
Compared To Tirzepatide, DA-1726 revealed comparable efficiency on weight-loss as well as enhanced plasma metabolic specifications.
Joe Hooker, Meantime Head Of State as well as Chief Executive Officer of NeuroBo, highlighted that DA-1726 remains in preclinical advancement for excessive weight as well as NASH, with strategies to launch a stage 1a security research in 1H of 2024.
Cost Activity: NRBO shares are up 4.35% at $0.41 on the last check Tuesday.
